Two-drug regimen of dolutegravir plus lamivudine (DTG+3TC) is noninferior to dolutegravir plus tenofovir/emtricitabine (DTG+TDF/FTC) at 48 weeks in antiretroviral treatment-naive adults with HIV-1 infection: subgroup analyses in the GEMINI studies. Issue 1 (January 2019)

• Record Type: Journal Article
• Authors: Orkin, C.; Porteiro, N.; Berhe, M.; Dretler, R.; Viciana, P.; Tseng, Y.; Oprea, C.; Johnson, M.; Kulagin, V.; Man, C.; Sievers, J.; Currie, A.; Underwood, M.; Tenorio, A.; Pappa, K.; Wynne, B.; Aboud, M.; Smith, K.; Gartland, M.; Steinhart, C.; Gatell, J.
• Is Part Of: Journal of infection and public health. Volume 12:Issue 1(2019)
• Page Start: 147
• Publication Date: 2019-01
• Subjects: Communicable diseases -- Periodicals; Public health -- Periodicals; Epidemiology -- Periodicals; Nosocomial infections -- Prevention -- Periodicals; Medical microbiology -- Periodicals; 614.4
• DOI: 10.1016/j.jiph.2018.10.127
• Languages: English
• ISSNs: 1876-0341